A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

Exclusion Criteria

• •History of severe allergic reaction or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of the lebrikizumab injection
• •Maintenance oral corticosteroid therapy within 3 months prior to Visit 1
• •Treatment with systemic (oral, intravenous \[IV\], or intramuscular \[IM\]) corticosteroids within 4 weeks prior to Visit 1 or during the screening period
• •Treatment with intra-articular corticosteroids within 4 weeks prior to Visit 1 or during the screening period or anticipated need for intra-articular corticosteroids during the course of the study
• •Infection that meets the following criteria: Any infection requiring hospital admission or requiring treatment with IV or IM antibiotics within 4 weeks prior to Visit 1 or during screening; any active infection that required treatment with oral antibiotics within 2 weeks prior to Visit 1 or during screening; upper or lower respiratory tract infection within 4 weeks prior to Visit 1 or during screening; active parasitic infection or Listeria monocytogenes infection within 6 months prior to Visit 1 or during screening
• •History of active tuberculosis requiring treatment
• •Known immunodeficiency, including, but not limited to, human immunodeficiency virus (HIV) infection
• •Evidence of acute or chronic hepatitis or known liver cirrhosis
• •History of cystic fibrosis, bronchiectasis, and/or other clinically significant lung disease other than asthma
• •Diagnosis or history of malignancy or current evaluation for potential malignancy
• •Current smoker or former smoker with a history of greater than (\>) 10 pack-years
• •History of alcohol or drug abuse
• •Past and/or current use of any anti- interleukin (IL) -13 or anti-IL-4/IL-13 therapy, including lebrikizumab
• •Use of other monoclonal antibody therapy, including omalizumab, within 6 months or 5 drug half-lives (whichever is longer) prior to Visit 1
• •Initiation of or change in allergen immunotherapy within 3 months prior to Visit 1 or during screening
• •History of bronchial thermoplasty